5. 進行性核上性麻痺 Progressive supranuclear palsy Clinical trials / Disease details


臨床試験数 : 89 薬物数 : 107 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108

  
9 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-001590-16-DE
(EUCTR)
02/07/201911/01/2019An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) Progressive Supranuclear Palsy (PSP)
MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: ABBV-8E12
Other descriptive name: ABBV-8E12
Product Code: ABBV-8E12
Other descriptive name: ABBV-8E12
AbbVie DeutschlandNULLNot RecruitingFemale: yes
Male: yes
330Phase 2United States;Canada;Australia;Germany
2EUCTR2016-001635-12-ES
(EUCTR)
04/07/201810/05/2018A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy.A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy Progressive Supranuclear Palsy
MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: ABBV-8E12
INN or Proposed INN: ABBV-8E12
Other descriptive name: ABBV-8E12
Product Code: ABBV-8E12
INN or Proposed INN: ABBV-8E12
Other descriptive name: ABBV-8E12
AbbVie Deutschland GmbH & Co. KGNULLNot RecruitingFemale: yes
Male: yes
330Phase 2United States;Canada;Spain;Australia;Germany;Italy
3EUCTR2017-001590-16-IT
(EUCTR)
27/04/201804/11/2020An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) - na Progressive Supranuclear Palsy (PSP)
MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: na
Product Code: ABBV-8E12
INN or Proposed INN: ABBV-8E12
ABBVIE DEUTSCHLAND GMBH & CO. KGNULLNot RecruitingFemale: yes
Male: yes
180Phase 2United States;Canada;Australia;Germany;Italy
4NCT03413319
(ClinicalTrials.gov)
April 17, 201823/1/2018Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104Progressive Supranuclear Palsy (PSP)Drug: ABBV-8E12AbbVieNULLCompleted18 YearsN/AAll3Phase 1United States
5NCT03391765
(ClinicalTrials.gov)
January 24, 20182/1/2018An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)Progressive Supranuclear Palsy (PSP)Drug: ABBV-8E12;Drug: Placebo solution for IV infusion on Day 15AbbVieNULLTerminated40 YearsN/AAll142Phase 2United States;Australia;Canada;Italy;Japan;France
6EUCTR2016-001635-12-DE
(EUCTR)
23/11/201720/02/2017A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy.A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy Progressive Supranuclear Palsy
MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: ABBV-8E12
Product Code: ABBV-8E12
Other descriptive name: ABBV-8E12
AbbVie Deutschland GmbH & Co. KGNULLNot RecruitingFemale: yes
Male: yes
330Phase 2United States;Canada;Spain;Australia;Germany;Italy
7EUCTR2016-001635-12-FR
(EUCTR)
26/10/201717/07/2017A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy.A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy Progressive Supranuclear Palsy
MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: ABBV-8E12AbbVie Deutschland GmbH & Co. KGNULLNot RecruitingFemale: yes
Male: yes
180Phase 2Canada;United States;Italy;France;Australia;Germany;Spain
8EUCTR2016-001635-12-IT
(EUCTR)
31/05/201705/02/2018A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy.A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy - NA Progressive Supranuclear Palsy
MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: ABBV-8E12
Product Code: ABBV-8E12
INN or Proposed INN: ABBV-8E12
ABBVIE DEUTSCHLAND GMBH & CO. KGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 2United States;Canada;Australia;Italy
9NCT02985879
(ClinicalTrials.gov)
December 12, 20161/12/2016A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: Placebo;Drug: ABBV-8E12AbbVieNULLTerminated40 YearsN/AAll378Phase 2United States;Australia;Canada;France;Germany;Italy;Japan;Spain